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Purpose: No clinically useful target molecule has been identified for triple-negative (TN) breast cancer, i.e., estrogen re-
ceptor-negative, progesterone receptor-negative, human epidermal growth factor receptor-2-negative phenotype, and its 
prognosis is poor. The aim of this study is to clarify the clinical and pathologic characteristics of triple negative breast cancer 
(TNBC). Methods: The study subjects, 87 women with TNBC, were a subset of patients operated at Kosin University Gospel 
Hospital from January 2000 to December 2005. We examined pathologic characteristics such as tumor necrosis, infiltrating 
border, lymphocytic infiltration, prominent nucleoli in TNBC. And we studied the correlation between TNBC and several 
factors related to pathologic morphology. Chi-squared tests were used for statistical analysis. Kaplan-Meier estimates are 
presented for the survival function, and differences in survival were analyzed using the log rank test. Results: Tumor necrosis 
was found in 51 patients (58.3%) in TNBC. And infiltrating border was found in 71 patients (81.0%). Also continuous lym-
phocytic distribution and prominent nucleoli was found in 31 patients (35.7%), 52 patients (59.7%), respectively. No associa-
tion was detected between pathologic characteristics and other biological markers. Patients with tumor necrosis positive for 
TNBC didn’t show shorter disease-free survival (P = 0.4490) or overall survival (P = 0.979) than patients without tumor 
necrosis. Conclusion: These findings suggest that pathologic characteristics cannot be used to classify triple-negative breast 
cancer into only two subtypes with differing prognoses. But because our study is small size study, more abundant patients’ 
dates will be needed to evaluate the morphologic characteristics’ predictive role.
Key Words: Triple negative breast cancer, Tumor necrosis, Lymphocytic infiltration, Prominent nucleoli
INTRODUCTION
  By using DNA microarray techniques, it has been 
shown that breast cancers can be classified into bio-
logically distinct groups based on their gene expression 
profiles. These groups comprise luminal A (estrogen re-
ceptor [ER]-positive and human epidermal growth factor 
receptor-2 [HER2]-negative), luminal B (ER- and HER2- 
positive), HER2 (ER-negative and HER2-positive), and tri-
ple negative (ER- and HER2-negative) subtypes [1,2]. The 
TNBC is a heterogeneous group and is further categorized 
into the basal-like and the normal breast subtypes, which 
are positive and negative, respectively, for myoepi-
thelial/basal markers such as basal cytokeratins (CKs) (i.e., 
CK5/6, CK14, and CK17), a-smooth muscle actin, and epi-
dermal growth factor receptor (EGFR) [3,4]. Although Dong Won Ryu, et al.
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Table 1. Antibodies, dilutions, incubation times, and cutoff values
Marker Species Manufacturer Dilution Incubation time Cutoff value
ER Mouse mAb Dako 　1：50 60 min, RT ≥10%
PgR Mouse mAb Dako 　1：100 60 min, RT ≥10%
HER2 Rabbit poly Dako 　1：250 60 min, RT 3＋  or FISH＋
Ki-67 Mouse mAb Dako 　1：50 60 min, RT ≥20%
p53 Mouse mAb Dako 　1：50 60 min, RT ≥10%
CK5/6 Mouse mAb Dako 　1：100 60 min, RT ≥5%
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor-2; RT, room temperature; FISH, 
fluorescence in situ hybridization.
TNBCs account for only 10 to 17% of all breast carcinomas, 
this subgroup is regarded as important clinically because 
of the aggressive clinical behavior, poorer patient prog-
nosis, and lack of an established therapeutic target [5,6]. 
The ratio of basal-like subtype in TNBC was estimated to 
be up to 56 to 84%. Therefore, characteristic histopatho-
logical features of TNBCs are similar with those of the bas-
al-like subtype [7,8]. Characteristic histopathological 
types that constitute TNBCs and basal-like subtype are 
high-grade invasive ductal carcinoma of no special type, 
typical medullary carcinoma, metaplastic carcinomas, 
and adenoid cystic carcinoma [1,9]. So we present data of 
histological features of TNBCs and discuss about its mor-
phological spectrum in our hospital case. 
METHODS 
Patients and tissue samples 
Tissue samples were obtained from 618 patients with 
invasive breast cancer who were diagnosed from 2000 to 
2005 at Kosin University Gospel Hospital in Busan, Korea. 
A total of 618 specimens of primary invasive carcinoma 
were obtained from resected tumor. None of these cancer 
patients received treatment prior to surgery. The patients 
underwent standard and partial mastectomies with fully 
resected axillary dissections. Patients received anthracy-
cline-containing chemotherapy if the tumor was node 
positive. Endocrine therapy was given for 5 years to pa-
tients with ER-positive tumors. Median follow-up was 5.5 
years (range, 0.3 to 14.8 years), during which there were 84 
relapses and 32 deaths. 
Immunohistochemical techniques 
The expression of ER, progesterone receptor, HER2, 
CK5/6 and other biological markers was determined im-
munohistochemically in paraffin-embedded tissue speci-
mens. Table 1 summarizes all the antibodies, dilutions, in-
cubation times, and cutoff values used for this analysis. All 
data were collected from the pathology reports. Histo-
pathological features such as hormone receptor status and 
HER2/neu status on immunohistochemistry (Dako, Co-
penhagen, Denmark) were all analyzed at the Institute of 
Pathology at the Kosin University Gospel Hospital. 
Expressions of p53, ERa, Ki-67, and ErbB2 were de-
termined immunohistochemically on paraffin sections us-
ing antibodies against ERa (Dako), Ki67 (Dako), ErbB2 
(Dako), p53 (Dako). Tumor necrosis was defined as the 
presence of necrosis of any dimension in a section of in-
vasive cancer. Histologic grading was performed using 
the criteria of Bloom and Richardson. Lymphatic vascular 
invasion was defined as the presence of tumor emboli in 
peritumoral lymphatic spaces, capillaries or postcapillary 
venules. ER status and progesterone receptor status were 
taken as positive if more than 10% of tumor cells showed 
staining. Immunohistochemical score of 3＋ or fluore-
scence in situ hybridization＋ for HER2 was accepted as 
HER2 positivity. 
Statistical analysis 
Statistical tests were performed using the SPSS ver. 12.0 
(SPSS Inc., Chicago, IL, USA). The survival function was 
calculated from the time of the pathologic diagnosis to the 
occurrence of death. Survival data were censored on 
December 31, 2009, which was the date on which the sur-Morphologic characteristics in TNBC
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Table 2. Patients and tumor characteristics 
Characteristics No. of patients (%)









　N2   70 (11.3)




　IIb   94 (15.2)
　IIIa   63 (10.2)
　IIIb 12 (1.9)
　IIIc   68 (11.0)
Histologic grade
　G1     81 (13.1)
　G2   230 (37.2)
　G3   307 (49.7)
p53 status
　Negative   581 (94.0)
　Positive   37 (5.9)
Ki67
　Negative     87 (14.1)
　Positive 531 (8.5)
Microarray
　Luminal A 166 (29.9)
　Luminal B 178 (28.9)
　HER2 162 (26.3)
　TNBC 111 (17.9)
Values are presented as mean (range) or number (%).
HER2, human epidermal growth factor receptor-2; TNBC, triple 
negative breast cancer.
Table 3. Patients and triple negative breast tumor characteristics 








T1 15 (29.4) 17 (47.2) 32 (36.8)
T2 29 (56.9) 15 (41.7) 44 (50.6)
T3  7 (13.8)   4 (11.1) 11 (12.6)
pN 0.615
0 26 (52.0) 18 (50.0) 44 (51.2)
1 12 (24.0)   8 (22.0) 20 (23.3)
2  8 (16.0)   4 (11.1) 12 (14.0)
3  4 (8.0)   6 (16.7) 10 (11.6)
AJCC stage 0.983
I 12 (24.5)   9 (25.0) 21 (24.7)
IIa 15 (30.6) 11 (30.6) 26 (30.6)
IIb 10 (20.4)   8 (22.2) 18 (21.2)
IIIa  7 (14.3)   1 (2.8)   8 (9.4)
IIIb  0 (0)   1 (2.8)   1 (1.2)
IIIc  3 (6.1)   6 (16.7)   9 (10.6)
Grading 0.983
G1  4 (10.3)   3 (10.3)   7 (10.3)
G2 10 (25.6)   8 (27.6) 18 (26.5)
G3 25 (64.1) 18 (62.1) 43 (63.2)
p53 0.538
Negative 23 (46.9) 15 (45.5) 38 (46.3)
Positive 26 (53.1) 18 (54.5) 44 (53.7)
Ki67 0.210
Negative  8 (16.7)   9 (26.5) 17 (20.7)
Positive 40 (83.3) 25 (73.5) 65 (79.3)
Values are presented as no. of patients (%).
AJCC, American Joint Committee on Cancer.
vival data were correlated with the death registry for the 
last time or 5 years after the onset of the disease. 
Kaplan-Meier estimates are presented for the survival 
function, and differences in survival were analyzed using 
the log rank test. Associations between specific histo-
pathological and clinical survival estimates and curves 
were established using the Kaplan-Meier method and dif-
ferences in observed survival distribution among patient 
subgroups were tested with two-sided log-rank test. All 
survival rates were presented with their standard errors. 
We used Pearson's correlation to determine the association 
of pairs of explanatory variables and differences in qual-
itative variables were evaluated by chi-squared test, 
where necessary. All P-values were two-sided and a P-val-
ue of less than 0.05 was considered to indicate a statisti-
cally significant difference.
RESULTS 
The main clinicopathological characteristics of the pa-
tients in our series are summarized in Table 2. Mean age 
was 54 years. Luminal A was reported in 166 patients 
(26.9%). Luminal B, HER2 and triple negative type was re-
ported in 178 patients (28.9%), 162 patients (26.3%), 111 pa-
tients (17.9%), respectively. Among the 111 TNBC pa-
tients, twenty four had missing data as a result of a com-Dong Won Ryu, et al.
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Table 4. Cytological findings of triple negative breast tumor 








 Yes 35 (54.8) 16 (66.6) 51 (58.3)
 No 28 (45.2)   8 (33.3) 36 (41.7)
Border 0.947
 Pushing   4 (6.5)   1 (4.2)   5 (6.0)
 Borderline   8 (12.9)   3 (12.5) 11 (13.0)
 Infiltrating 51 (80.6) 20 (83.3) 71 (81.0)
Lymphocyte 0.360
 Cuffing   3 (4.8)   0 (0)   3 (3.6)
 Continous 20 (32.3) 11 (45.8) 31 (35.7)
 No 40 (62.9) 13 (54.2) 53 (60.7)
Nucleoli 0.348
 Prominent 34 (54.7) 18 (75.0) 52 (59.7)
 Moderate 29 (45.3)   6 (25.0) 35 (40.3)
Values are presented as no. of patients (%).
Fig. 1. Kaplan-Meier estimates for disease-free survival according 
to tumor necrosis.
Table 5. Five years overall and disease-free survival probabilities in triple negative breast cancer as calculated by Cox proportional hazards 
regression model (P-value for log rank test)
DFS OS
HR 95% CI P-value HR 95% CI P-value
pT 3.476 1.390-8.693 0.008 5.956 1.317-26.92 0.020
pN 1.690 1.144-2.495 0.008 2.496 1.142-5.454 0.022
AJCC stage 1.060 1.011-1.111 0.016 1.119 0.970-1.293 0.124
Grade 0.678 0.349-1.699  0.1830 0.830 0.467-2.897  0.1167
p53 0.750 0.270-2.083  0.5820 0.564 0.562-2.678  0.6217
Ki-67 1.564 0.678-2.347  0.0546 0.863 0.435-2.967  0.1259
CK5/6 0.371 0.047-2.922  0.3257 0.786 0.327-6.879  0.2752
Necrosis 1.548 0.499-4.802  0.4490 1.024 0.171-6.133 0.979
Lymphocyte infiltration 2.038 0.587-7.075  0.2620 1.567 0.534-6.786 0.543
Prominent nucleoli 0.553 0.214-1.429  0.2210 1.053 0.309-3.592 0.934
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer.
puter failure, so that 87 TNBC patients are included in the 
final morphologic characteristics data set. Other reasons 
for ineligibility included incompetent specimen. Tumor 
necrosis was found in 51 patients (58.3%) in TNBC. And 
infiltrating border was found in 71 patients (81.0%). Also 
continuous lymphocytic distribution and prominent nu-
cleoli was found in 31 patients (35.7%), 52 patients (59.7%), 
respectively. No association was detected between patho-
logic characteristics and other biological markers (Table 
3). Among TNBC patients, 87 patients could be studied 
about CK5/6. According to the positivity of CK5/6, 24 of 
the 87 patients (27.6%) had been diagnosed as CK5/6 (＋) 
TNBC and 63 patients (72.4%) had CK5/6 (−) TNBC (Table 
4). No statistical relationship was found between CK5/6 
positivity and the other variables, such as tumor size, no-
dal status, American Joint Committee on Cancer stage, tu-
mor grading, p53 and Ki67. Tumor necrosis was found in 
16 patients (66.6%) in CK5/6 (＋) TNBC. And infiltrating 
border was found in 20 patients (83.3%) in CK5/6 (＋) 
TNBC. Also continuous lymphocytic distribution and 
prominent nucleoli was found in 20 patients (32.2%), 34 
patients (54.7%) in CK5/6 (−) TNBC respectively. But 
there is no significant association between CK5/6 (＋) 
TNBC and morphologic characteristics (Table 4, Fig. 1). At Morphologic characteristics in TNBC
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a median follow-up of 5.5 years, 84 patients (13.6%) had a 
recurrence. And 32 patients (5.2%) had a death. Among 
TNBC, we observed 11 relapses in 63 patients (17.5%) with 
CK5/6 (−) TNBC and only 1 relaps in 24 patients (4.1%) 
with CK5/6 (＋) TNBC. Disease-free survivals was not 
shorter in patients with CK5/6 (＋) TNBC at diagnosis 
when compared with patients with CK5/6 (−) TNBC 
(hazard ratio [HR], 0.371; 95% confidence interval [CI], 
0.047 to 2.922; P = 0.3257). Also overall survival was not 
shorter in patients with CK5/6 (＋) TNBC (HR, 0.786; 95% 
CI, 0.327 to 6.879; P = 0.2752) (Table 5). 
DISCUSSION 
Among the high-grade invasive ductal carcinomas, a 
large part of cases is made up of high-grade solid-tubular 
carcinoma (also called as atypical medullary carcinoma) 
[1,10]. Typical medullary carcinoma is defined as a 
well-circumscribed carcinoma composed of poorly differ-
entiated cells arranged in large sheets syncytial archi-
tecture with scant stroma, with no glandular structures, 
and with a prominent lymphoplasmacytic infiltratation, 
and with a pushing border of invasion [11,12]. Central 
geographic or comedo-type necrosis may also be seen. 
Tumors showing the association of a predominantly syn-
cytial architecture with only two or three of the other 
above-mentioned criteria are designated as atypical me-
dullary carcinoma [13,14]. High-grade invasive ductal car-
cinoma with a large central acellular zone is also found rel-
atively frequently in TNBCs. The independent prognostic 
significance of tumor necrosis has been studied ex-
tensively [15,16]. Controversy exists about the definition 
and classification of necrosis, with respect to the amount 
of necrosis that is considered to be significant as well as the 
relative distribution of necrosis within intraductal and in-
vasive components of a tumor [17,18]. There is evidence 
indicating that the prognostic significance of tumor ne-
crosis is time dependent. For example, Gilchrist et al.   
found that tumor necrosis defined as the “presence of con-
fluent necrosis of any dimension in a section of invasive 
cancer that could be distinguished at intermediate magni-
fication,” was a significant predictor of time to recurrence 
and overall survival with 10-year follow-up [19,20]. And 
previous data add further support to the perception that 
extensive necrosis is a prognostically unfavorable feature 
in invasive mammary carcinoma, possibly reflecting a 
growth rate so rapid that it exceeds tumor sustaining an-
giogenesis to a substantial degree [21,22]. And the prog-
nostic significance of stromal inflammatory cells within 
and around invasive duct carcinomas has been the subject 
of considerable interest and some controversy [23,24]. The 
reaction consists mainly of mature lymphocytes with a 
variable admixture of plasma cell, histiocytes, neu-
trophils, and mast cells. Rarely, plasma cells or eosinophils 
predominate. Tumors with plasma cell predominance are 
usually medullary carcinomas or carcinomas with medul-
lary features [15,16]. The marked lymphoplasmacytic re-
action observed in medullary carcinoma also occurs in a 
minority of non medullary invasive duct carcinomas 
[17,18].
In conclusion, these findings suggest that morphologic 
characteristics cannot be used to classify TNBC into at 
least two subtypes with differing prognoses. One of the 
reasons is that only a small number of patients were exam-
ined in this study, making it difficult to reach statistical 
significance. More abundant patients’ date will be needed 
to evaluate of the morphologic characteristics’ predictive 
role.
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